Skip directly to content

UPDATE - PFIZER CANADA STATEMENT ON EPIPEN® AUTO-INJECTOR (0.3 MG) SUPPLY

23/08/18

Kirkland, QC, August 23, 2018 - Pfizer confirms the release of EpiPen® 0.3 mg auto-injectors across Canada and is continuing to work towards ensuring consistent supply.  Additional stock is expected to be released to the Canadian market in the coming weeks.  During this time of supply constraint, inventory will continue to be managed through measured national allocation. 

At this time, EpiPen® Jr 0.15 mg continues to be available and allocated at a national level to ensure market supply.

Pfizer continues to provide regular updates to Health Canada regarding this situation.

Pfizer Canada has asked Health Care Professionals to help manage supply for patients during this temporary supply interruption. As a result, pharmacists are filling prescriptions with the temporary supply interruption in mind. 

We understand and regret the challenges this situation continues to pose to patients.  Ensuring continuity of the supply of our medicines is paramount.

- 30 -

For more information, please contact:

Questions of a Medical nature, please call: Pfizer Canada Medical Information @ 1-800-463-6001;
www.pfizermedicalinformation.ca

Questions from Trade customers, please call: Customer Relations @ 1-800-387-4974.

If you are a member of the media, please call: Pfizer Canada Media Relations @ 1-866-9Pfizer (1-866-973-4937) email: [email protected]

_______________________________________________________________________________________________________________________________________

Statement posted on 30/07/18

Kirkland, QC, July 30, 2018 - Pfizer continues to experience supply shortages of EpiPen® epinephrine auto-injectors in the 0.3 mg and 0.15 mg doses.

Throughout 2018, there has been limited supply of auto-injectors at wholesalers, distributors and pharmacies in Canada.  Pfizer understands the importance of this medically-necessary medicine to Canadian patients and continues to take action to expedite delivery of product to the market.

Pfizer anticipates the next shipment of EpiPen® 0.3 mg to the Canadian market by late August 2018.  At which time, limited inventory will be available and will continue to be managed through measured allocation.  Until this new shipment arrives, shortages of EpiPen® 0.3 mg can be expected at the retail pharmacy level.

At this time, EpiPen® Jr 0.15 mg continues to be available and allocated at a national level to ensure market supply.

 Pfizer is providing regular updates to Health Canada regarding this situation.

Pfizer Canada has asked Health Care Professionals to help manage supply for patients during this temporary supply interruption. As a result, pharmacists are filling prescriptions with the temporary supply interruption in mind. 

We understand and regret the challenges this situation continues to pose to patients.  Ensuring continuity of the supply of our medicines is paramount.

- 30 -

For more information, please contact:

Questions of a Medical nature, please call: Pfizer Canada Medical Information @ 1-800-463-6001;
http://www.pfizermedicalinformation.ca/

Questions from Trade customers, please call: Customer Relations @ 1-800-387-4974.

If you are a member of the media, please call: Pfizer Canada Media Relations @ 1-866-9Pfizer (1-866-973-4937) email: [email protected]